



Revised Notice of Public Hearing

February 12, 2021

Ref. 2021-H-05
Revision 1

CNSC to conduct a public hearing on BWXT Medical Ltd. application for a Class IB licence

The Canadian Nuclear Safety Commission (CNSC) will hold a public hearing on June 9–10, 2021, to consider an application from **BWXT Medical Ltd. (formerly BWXT ITG Canada Inc.)** for a Class IB nuclear substance processing facility operating licence. BWXT Medical Ltd. is requesting a licence that would authorize it to operate an existing medical isotope facility located within a nuclear substance processing facility in Ottawa, Ontario. **This revised notice is to announce a change in the date for the filing of the recommendations from CNSC staff and the submission from BWXT Medical Ltd., and in the deadline for Indigenous peoples, members of the public and stakeholders to file an intervention.**

BWXT Medical Ltd. acquired the Nordion (Canada) Inc. (Nordion) medical isotope business on July 30, 2018. Since then, Nordion has continued to operate the medical isotope facility under its Class IB licence.

Date: June 9–10, 2021
Place: To be determined (at this time, a virtual hearing)
Time: As set by the agenda published prior to the hearing date

The public hearing will be webcast live and available on the CNSC website at nuclearsafety.gc.ca.

To assist Indigenous peoples, members of the public and stakeholders in reviewing BWXT Medical Ltd.'s application, and **as previously set out in the notice of public hearing published on November 18, 2020**, participant funding of up to \$75,000 was made available through the CNSC's [Participant Funding Program](#). The deadline to submit a completed participant funding application form to the CNSC was January 22, 2021.

BWXT Medical Ltd.'s licence application is posted on its [website](#). BWXT Medical Ltd.'s submission and CNSC staff's recommendations to be considered at the hearing will now be available on the CNSC website, or on request to the Secretariat, after **March 10, 2021**, instead of **February 24, 2021**.

Pursuant to rule 19 of the *Canadian Nuclear Safety Commission Rules of Procedure*, persons who have an interest or expertise in this matter or information that may be useful to the Commission in coming to a decision are invited to comment on BWXT Medical Ltd.'s application. Requests to intervene must be filed with the Commission Secretariat by **May 3**,

2021, using the [online request form](#) or the contact information below. **The request to intervene must include the following information:**

- a written submission of the comments to be presented to the Commission
- a statement setting out whether the requester wishes to intervene by way of written submission only or by way of written submission and oral presentation
- the requester's name, address, telephone number and email address

All submissions will be available for download on the CNSC website or on request to the Secretariat. Personal information, such as email address and telephone number, is essential for linking the submission to its author. If you wish to ensure the confidentiality of your personal information, please submit it on a separate page.

For further information on the public Commission hearing process, or on the applicant or the facility being considered in this matter, or to request documents, contact:

Senior Tribunal Officer, Secretariat
Tel.: 613-858-7651 or 1-800-668-5284
Fax: 613-995-5086
Email: cns.interventions.ccsn@canada.ca
Web: [Participate in a public Commission hearing](#)